News about "Serum Institute of India "

Serum Institute to Produce 100,000 Doses of Oxford Rift Valley Fever Vaccine

Serum Institute of India will produce up to 100,000 doses of an investigational Rift Valley fever vaccine developed by the University of Oxford, as the viral disease continues to affect parts of West Africa. The doses may be used for testing and future outbreak response, under an agreement supported by CEPI.

Serum Institute Of India | 17/01/2026 | By News Bureau

Valneva and Serum Institute End Chikungunya Vaccine Licensing Deal

Valneva SE and the Serum Institute of India have mutually agreed to discontinue their licensing agreement for Valneva’s single-shot chikungunya vaccine, bringing the collaboration to a close by mutual consent.

Serum Institute Of India | 01/01/2026 | By News Bureau

India Unveils its First Indigenous CRISPR-based Gene Therapy 'BIRSA 101' for Sickle Cell Disease

India has formally begun its decisive journey towards becoming a Sickle Cell Disease–free nation, with Union Minister of State for Science & Technology Dr. Jitendra Singh launching the country's first indigenous CRISPR-based gene therapy for the condition.

Serum Institute Of India | 20/11/2025 | By Dineshwori |  360

CEPI, SII and Oxford University Collaborate to Develop Nipah Virus Vaccine Reserve

CEPI, the Serum Institute of India, and the University of Oxford have partnered to produce ChAdOx1 NipahB vaccine doses for Phase II trials and an investigational reserve of up to 100,000 doses, ready for rapid deployment in case of a future Nipah outbreak.

Serum Institute Of India | 30/10/2025 | By Dineshwori |  280

Vidal Health and SII Collaborate on HPV Vaccine Access

Vidal Health and Serum Institute of India (SII) have partnered to boost cervical cancer prevention, launching from 1 October 2025 a first-of-its-kind cashless platform for HPV vaccination—covering digital bookings, consent, and certification with zero paperwork.

Serum Institute Of India | 24/09/2025 | By Dineshwori

SII Invests in IntegriMedical to Boost N-FIS Technology

Serum Institute of India (SII) has made a strategic investment in IntegriMedical, acquiring a 20 percent stake in the company, to advance Needle-Free Injection System technology.

Serum Institute Of India | 18/05/2024 | By Aishwarya |  495

SIIPL Signs Licensing Agreement with University of Oxford for Meningitis-B Vaccine

Serum Institute of India Pvt. Ltd. (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation in a significant stride towards addressing the challenge of Men-B disease.

Serum Institute Of India | 22/04/2024 | By Aishwarya |  583

SII Joins Hands with Univercells to Make Personalized Oncology Affordable

The new therapies are developed using genetic material extracted from the patient’s tumors, a process which is both time-consuming, and expensive.

Serum Institute Of India | 12/04/2024 | By Manvi |  554

Sanofi Receives Nod for IMOVAX-Polio in India

Sanofi has gained approval for IMOVAX-Polio, an alternative injectable vaccine.

Serum Institute Of India | 11/04/2024 | By Aishwarya |  516

Bharat Biotech Partners with Bilthoven Biologicals for Oral Polio Vaccines

Bharat Biotech has teamed up with Bilthoven Biologicals, a subsidiary of Serum Institute of India to produce and supply oral polio vaccines (OPVs) worldwide.

Serum Institute Of India | 05/04/2024 | By Aishwarya |  737